Screener
UroGen Pharma URGN Return on equity
Discontinued — last reported Q4 '21
Return on equity at other companies
Other financials
Where this comes from
Calculated from UroGen Pharma’s reported figures.
Based on trailing twelve months.
The source filing: UroGen Pharma’s 10-K, filed March 24, 2023. Open the filing →
- Filed
- Mar 24, 2023
- Fiscal year
- FY2022
- Accession
- 0001437749-23-007710
FAQ
- What is UroGen Pharma's return on equity?
- UroGen Pharma (URGN) reported return on equity of -211.6% in Q4 2021.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about UroGen Pharma's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude